Latest News

As part of National Women Physicians Day, a group of women clinicians discussed various topics in the care for women with movement disorders.

Riley Bove, MD, MS, associate professor of neurology at the University of California San Francisco, shares her personal view on National Women’s Physician’s and why it’s important for clinicians and patients in the field.

Epilepsy titan Page B. Pennell, MD, FAES, FAAN, FANA, outlined key hormonal, reproductive, and treatment-related factors that influence epilepsy management and outcomes for women in different life stages.

Claire Henchcliffe, MD, DPhil, an international leader in Parkinson disease research, reflects on mentorship, leadership development, and the systemic changes needed to support long-term success for women in neurology and clinical neuroscience.

In honor of National Women Physicians Day, held February 3, 2026, a trio of women clinicians highlighted the importance of individualized care for women living with multiple sclerosis.

Janis Miyasaki, MD, MEd, FRCPC, FAAN, a pioneer in neuropalliative care, provided clinical thoughts and perspectives on National Women Physicians Day and the ways to promote women leadership within the neurology field.

The FDA approves the FreedomEDGE infusion platform for rozanolixizumab, enhancing treatment options for generalized myasthenia gravis in clinical settings.

Here's some of what is coming soon to NeurologyLive® this week.

Anti–interleukin-6 receptor therapy may offer a new treatment option for patients with NMOSD and MOGAD who do not respond to rituximab, according to new findings.

Neurocrine Biosciences launches a Phase 2 trial for NBI-1065890, targeting tardive dyskinesia with promising new treatment options.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 30, 2026.

The AAN's new guideline enhances diagnosis and management of functional seizures, emphasizing psychological interventions and addressing care gaps for better patient outcomes.

Specifically, the alignment relates to a separate, planned clinical trial referred to as ASPIRE.